Sumitomo/Myovant: Agreed Minorities Takeout at $27
There is a willing buyer, Sumitomo, which has increased its offer by 18.7% vs. the initial approach. The market believes the offer will succeed and...
Sumitomo Dainippon Pharma Co (4506 JP): Myovant Is Crucial for Post-Latuda Growth Momentum
As Sumitomo is not expected to launch any new in-house product until FY24, the company needs Myovant’s already marketed products to maintain its...
Sumitomo/Myovant: Minorities Takeout
The question is whether Orgovyx could become a blockbuster. The market certainly thinks so, there may be both further upside potential in the...
Myovant Sciences (MYOV US): Rejects Sumitomo’s $2.5B Bid; Remains Open for Better Offer
Myovant has turned down acquisition offer from its largest shareholder, leading to share price volatility. A revised offer or a fresh offer from...
Another Bear Market Rally Brewing?; Stick With Biotech and Construction/Engineering Names
Early indications suggest another bear market rally in $SPX, and potentially that the lows are in, helped by short-term bearish engulfing patterns...
No more insights